SPG302 (Tazbentetol) Phase 2a — Synapse Density Modulator for ALS
SPG302 — also called tazbentetol — is a first-in-class once-daily oral drug designed to restore glutamatergic synapses between neurons. Developed by Spinogenix, it represents a novel hypothesis in ALS treatment: that preserving or rebuilding synaptic connections between motor neurons might slow functional decline, rather than targeting the inflammatory or genetic mechanisms that most other ALS therapies approach. The Phase 2a trial enrolled 23 ALS participants and reported 76% slower rate of decline at six months compared to PRO-ACT historical controls, with 82% of participants showing stable or improved ALSFRS-R trajectories. FDA has authorized an expanded access program for up to 200 ALS patients.
Mechanism of action: restoring glutamatergic synapses
Motor neurons communicate with each other and with downstream cells via synapses. In ALS, these synaptic connections deteriorate and are lost as the disease progresses. Conventional ALS therapies focus on either reducing the rate of motor neuron death (riluzole's glutamate antagonism, edaravone's antioxidant approach) or addressing specific genetic drivers (tofersen for SOD1-ALS). SPG302 takes a different approach: it targets the restoration of glutamatergic synaptic density — the number and quality of excitatory synaptic connections — rather than preventing neuron loss directly.
The hypothesis is that preserving synaptic architecture may maintain motor function even as some neurodegeneration continues — keeping the surviving motor neurons connected and functional longer than they would be without intervention. In animal models of ALS and other neurodegenerative conditions, SPG302 has been shown to increase synapse density and improve motor function. EEG findings in the Phase 2a trial provided additional biological evidence: ALS-associated brain activity patterns improved in treated participants, consistent with the proposed synaptic mechanism.
What they did
The Phase 2a trial (NCT05882695) enrolled 23 adults with ALS. The trial had a two-part design: a 28-day initial period that was randomized and placebo-controlled, followed by a 140-day open-label active treatment period in which all participants received SPG302 at 300 mg daily. This design was powered to assess safety and early biological signals over the short randomized phase, with the longer open-label phase allowing assessment of functional trajectory.
The 6-month efficacy analysis compared the ALSFRS-R trajectories of the SPG302-treated participants against the PRO-ACT historical control database — a large, well-characterized dataset of ALS patient outcomes used as a historical comparator in the absence of a concurrent placebo arm for the full 6-month period.
What they found
At the end of the 6-month treatment period, SPG302-treated participants showed an average 76% slower rate of ALSFRS-R decline compared to the PRO-ACT historical controls matched for baseline characteristics. This is a very large apparent effect size, though it must be interpreted cautiously given the small sample and the historical control comparator rather than a concurrent randomized placebo group.
82% of SPG302-treated participants exhibited a stable or improved ALSFRS-R rate of decline at the end of treatment — meaning the majority of participants either maintained function or showed functional improvement during the treatment period. This proportion is substantially higher than what would be expected from the natural history of ALS.
EEG recordings in a subset of participants showed improvements in ALS-associated brain activity patterns after treatment, providing biological evidence consistent with the proposed synaptic restoration mechanism.
SPG302 was well tolerated at 300 mg daily. No treatment-related serious adverse events were reported over 6 months.
Based on these results, FDA granted Orphan Drug Designation for ALS and cleared an Expanded Access Program allowing up to 200 ALS patients who are not in a clinical trial to receive SPG302 outside of the trial context. EMA has also granted Orphan Drug Designation.
Why it matters
A 76% slowing in a Phase 2a trial is a remarkable number. It is also a number that requires the appropriate caution that all Phase 2 results demand: ALS drug development history is littered with therapies that showed strong Phase 2 signals and then failed to demonstrate efficacy in larger, well-controlled Phase 3 trials. The 23-patient sample is small. The historical control comparison, while methodologically accepted in ALS research and supported by the FDA for certain purposes, is not equivalent to a concurrent randomized placebo group.
That said, two things distinguish the SPG302 Phase 2a result. First, the mechanism is genuinely novel — synaptic restoration has not been directly targeted in prior ALS trials, and the EEG evidence provides some biological plausibility for the functional findings. Second, the FDA's decision to authorize an expanded access program for 200 patients reflects regulatory confidence that the safety profile and preliminary efficacy signal are sufficient to justify broader access before Phase 3 data are available.
The next step for SPG302 is a Phase 3 randomized trial. That trial design and timeline had not been announced as of April 2026, but the expanded access program will continue to generate real-world data in a larger patient population while it is planned.
PLS relevance
SPG302 is being studied exclusively in ALS at this stage. The synaptic restoration mechanism is theoretically relevant to any condition involving motor neuron dysfunction, including PLS — the upper motor neurons in PLS also lose synaptic connections as the disease progresses. However, there is no published data on SPG302 in PLS, and PLS patients are not eligible for the current trial or expanded access program, which requires an ALS diagnosis.
If Phase 3 results confirm efficacy in ALS, the question of whether the same approach works in PLS — where the synaptic loss occurs specifically at the cortical upper motor neuron level — would be worth investigating in a dedicated study.
How this connects
SPG302 is one of several active ALS drug programs with Phase 2 positive signals advancing toward Phase 3. For the broader context, see Drug Trial Research. For comparison with another Phase 2 positive result, see PrimeC PARADIGM. For a trial currently in Phase 3 and enrolling, see Pridopidine PREVAiLS. Information on how to find open trials is at Clinical Trials.
Citation
Spinogenix, Inc. SPG302 (tazbentetol) Phase 2a ALS trial (NCT05882695): topline clinical trial results. Presented November 2025. FDA Orphan Drug Designation and Expanded Access Program (200 patients) authorized. EMA Orphan Drug Designation granted.